We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+21.28%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.03B
AUM Growth
+$384M
Cap. Flow
+$76.6M
Cap. Flow %
3.78%
Top 10 Hldgs %
49.69%
Holding
79
New
15
Increased
27
Reduced
15
Closed
14
Avg Time Held Equity + Options
1.1 years
Top 10 Avg Time Held Equity + Options
1.2 years
Top 20 Avg Time Held Equity + Options
1.1 years
Avg Time Held Equity only
1.1 years
Top 10 Avg Time Held Equity only
1.2 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$71M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$60.3M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$44.3M
4
NITE icon
Nightstar Therapeutics plc American Depositary Shares
NITE
+$38.2M
5
INSM icon
Insmed
INSM
+$37.7M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$66.3M
2
ELV icon
Elevance Health
ELV
+$43.6M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$35M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$32M
5
PEN icon
Penumbra
PEN
+$31.5M

Sector Composition

Rank Sector Weight
1 Healthcare 94.27%
2 Financials 3.41%
3 Miscellaneous 1.69%
4 Communication Services 0.62%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARRY icon
1
DELISTED
Array Biopharma Inc
ARRY
$216M 10.65%
17,556,586
+1,462,800
+9% +$13.6M
2013 Q2
17 quarters
FOLD icon
2
DELISTED
Amicus Therapeutics
FOLD
$166M 8.19%
11,012,561
-1,031,371
-9% -$13.6M
2013 Q2
17 quarters
PBYI icon
3
Puma Biotechnology
PBYI
$549M
$109M 5.36%
906,642
+46,186
+5% +$4.3M
2016 Q3
4 quarters
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$100M 4.95%
1,843,733
+1,178,594
+177% +$60.3M
2014 Q3
12 quarters
CLVS
5
DELISTED
Clovis Oncology, Inc.
CLVS
$82.1M 4.05%
996,610
+232,221
+30% +$18.4M
2013 Q2
17 quarters
ALDR
6
DELISTED
Alder Biopharmaceuticals
ALDR
$79.3M 3.91%
6,476,766
+4,252,955
+191% +$44.3M
2016 Q3
4 quarters
AZN icon
7
AstraZeneca
AZN
$260B
$76.1M 3.75%
+1,123,150
New +$71M
2017 Q3
0 quarters
INSM icon
8
Insmed
INSM
$21.4B
$62.2M 3.07%
1,991,646
+1,979,266
+15,988% +$37.7M
2017 Q2
1 quarter
IMGN icon
9
DELISTED
Immunogen Inc
IMGN
$61.7M 3.04%
8,061,497
+2,848,761
+55% +$18.9M
2017 Q1
2 quarters
RGNX icon
10
Regenxbio
RGNX
$462M
$55M 2.71%
1,667,672
-50,999
-3% -$1.15M
2017 Q1
2 quarters
PEN icon
11
Penumbra
PEN
$12.6B
$51.1M 2.52%
565,511
-365,933
-39% -$31.5M
2015 Q3
8 quarters
WVE icon
12
Wave Life Sciences
WVE
$617M
$49.3M 2.43%
2,267,707
+43,300
+2% +$870K
2015 Q4
7 quarters
ATRA icon
13
Atara Biotherapeutics
ATRA
$97.8M
$47.8M 2.36%
115,588
+6,226
+6% +$2.35M
2014 Q4
11 quarters
LIVN icon
14
LivaNova
LIVN
$4.3B
$44.3M 2.19%
632,488
+420,460
+198% +$26.6M
2017 Q2
1 quarter
CNC icon
15
Centene
CNC
$34.9B
$39.2M 1.93%
809,200
+12,800
+2% +$551K
2017 Q2
1 quarter
ICUI icon
16
ICU Medical
ICUI
$4.15B
$37.5M 1.85%
201,750
+69,245
+52% +$12.1M
2017 Q1
2 quarters
AET
17
DELISTED
Aetna Inc
AET
$37.2M 1.83%
+233,837
New +$36.5M
2017 Q3
0 quarters
BOLD icon
18
DELISTED
Audentes Therapeutics, Inc
BOLD
$36.1M 1.78%
1,289,332
-170,284
-12% -$3.7M
2016 Q3
4 quarters
OXFD
19
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$34.5M 1.7%
2,051,487
-104,462
-5% -$1.7M
2013 Q4
15 quarters
GWPH
20
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$34.4M 1.69%
338,536
-106,400
-24% -$11.4M
2016 Q3
4 quarters
EHTH icon
21
eHealth
EHTH
$19M
$32M 1.58%
1,337,623
+114,289
+9% +$2.33M
2016 Q4
3 quarters
MOH icon
22
Molina Healthcare
MOH
$11.1B
$31.7M 1.56%
461,074
-367,500
-44% -$23.9M
2016 Q1
6 quarters
PRAH
23
DELISTED
PRA Health Sciences, Inc.
PRAH
$30.6M 1.51%
+402,014
New +$30.4M
2017 Q3
0 quarters
ELGX
24
DELISTED
Endologix Inc
ELGX
$29.2M 1.44%
654,468
+17,638
+3% +$804K
2015 Q4
7 quarters
NITE icon
25
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$28.8M 1.42%
+1,769,346
New +$38.2M
2017 Q3
0 quarters
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2017 Portfolio in Review

As of Q3 2017, Redmile Group held 79 positions worth $2.03B, up 23% from $1.64B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Redmile Group deployed $76.6M of net new capital in Q3 2017, opening 15 new positions and adding to 27 existing holdings. Its largest new stake was AstraZeneca: 1,123,150 shares worth $76.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Syneos Health, Inc. Class A Common Stock, an estimated $32M trimmed.

  • Redmile Group's largest Q3 2017 buy was AstraZeneca: 1,123,150 shares worth $76.1M.
  • Redmile Group added most to Seagen Inc. Common Stock in Q3 2017, an estimated $60.3M increase.
  • Redmile Group's biggest Q3 2017 reduction was Syneos Health, Inc. Class A Common Stock, cutting an estimated $32M.
  • Redmile Group fully exited Juno Therapeutics, Inc. in Q3 2017, selling an estimated $66.3M.
  • Redmile Group's ten largest holdings make up 50% of its $2.03B portfolio in Q3 2017.
  • Redmile Group opened 15 new positions and closed 14 in Q3 2017.
  • Redmile Group's portfolio value rose 23% quarter-over-quarter to $2.03B.

Based on Redmile Group's 13F filing for Q3 2017, filed 14 Nov 2017.